Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ChemoCentryx, Inc. - Common Stock (NQ: CCXI )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 51.97 (10)
Ask (Size) 52.00 (55)
Prev. Close 51.99
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 71,355,872
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga

Performance

More News

Read More
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
From ChemoCentryx, Inc.
Via GlobeNewswire
Biotech Stocks Well-Positioned For The Fourth Quarter
Via Talk Markets
ChemoCentryx: Q2 Earnings Insights
Via Benzinga
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From ChemoCentryx, Inc.
Via GlobeNewswire
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
Via Talk Markets
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
From Scott+Scott Attorneys at Law LLP
Via Business Wire
7 Dow Stocks With Superior Fundamentals
Via InvestorPlace
Healthcare Sector Still Looks Good But Lacks Momentum
Via Talk Markets
ChemoCentryx's Return On Capital Employed Insights
Via Benzinga
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
From Scott+Scott Attorneys at Law LLP
Via Business Wire
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
Via Investor's Business Daily
Whither Small Caps After Fed’s Tough Talk?
Via Talk Markets
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
Via Investor's Business Daily
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
Via Talk Markets
Why Jim Cramer Says This Financial Stock Is 'Terrific'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
Via Benzinga
Earnings Preview: ChemoCentryx
Via Benzinga
Small Cap Biotechs Perk Up On Dealmaking
Via Talk Markets
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
Via Investor's Business Daily
Where ChemoCentryx Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.